| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | U100 |
| Uniprot No | Q9QJ11 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-354aa |
| 氨基酸序列 | TVHRDAGTVESTPPPDDEDNYTAKYYDDSIYFNIYDGTNPTPRRRTLPEIISKFSTSEMSRLGGLKAFVPVDYTPTTTLEDIEDLLNYAICDDNSCGCLIETEARSMFGDIIICVPLSAESRGVRNLKSRIMPMGLSQILSSGLGLHFSLLYGAFGSNYNSLAYMERLKPLTAMTAIAFCPMTSKLELRQNYRLEKARSNLIVNIELLKIQNHGGQTIKTLTSFAIVRKDSDGQDWETCTRFASVSIEDILRSKPAANGTCCPPRDVHHDRPTLQSSNSWTRTEYFEPWQDVVDAYVPINDNHCPNDSYVVFQTLQGHEWCSRLNKNDTK |
| 预测分子量 | 44.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于假设“U100重组蛋白”可能指向胰岛素类似物或相关重组蛋白药物的文献示例(注：内容为模拟生成，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *Efficacy and Safety of U-100 Insulin Analogs in Type 2 Diabetes*
**作者**: Klein O, et al.
**摘要**: 本研究评估了U-100浓度重组胰岛素类似物(如德谷胰岛素)在2型糖尿病患者中的长期疗效与安全性。结果显示，与传统胰岛素相比，U-100制剂能更稳定地控制血糖，且低血糖风险显著降低。
2. **文献名称**: *Pharmacokinetics of U-100 Aspart in Pediatric Populations*
**作者**: White JR, et al.
**摘要**: 通过对比儿童与成人群体中U-100门冬胰岛素的药代动力学特性，研究发现儿童需调整剂量以匹配代谢差异，但总体安全性与成人相当，支持其在儿科糖尿病治疗中的应用。
3. **文献名称**: *Cardiovascular Outcomes of U-100 Recombinant Insulin Therapy*
**作者**: Marso SP, et al.
**摘要**: 大规模临床试验(纳入10.000例患者)表明，U-100重组胰岛素治疗未增加心血管事件风险，且在合并心血管疾病的糖尿病患者中表现出潜在的心肾保护作用。
4. **文献名称**: *Cost-effectiveness of High-Concentration U-100 Insulins*
**作者**: Hunt B, et al.
**摘要**: 分析显示，尽管U-100胰岛素类似物价格较高，但其减少并发症和住院率的长期效益使其具有更高的成本效益，尤其适用于需大剂量注射的患者。
---
**注意**：以上内容为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如“U-100 insulin”、“recombinant insulin analogs”)获取。若“U100重组蛋白”指向其他特定蛋白，建议提供更多背景信息以便精准查询。
**Background of U100 Recombinant Protein**
U100 recombinant protein is a bioengineered molecule designed to address specific therapeutic or diagnostic challenges in biomedicine. Its development stems from advances in recombinant DNA technology, which enables the precise modification and production of proteins in heterologous expression systems (e.g., bacteria, yeast, or mammalian cells). U100 is typically engineered to enhance stability, bioavailability, or target-binding affinity compared to its native counterpart, making it suitable for applications where natural proteins may fail due to rapid degradation or immunogenicity.
The design of U100 often incorporates domain-specific modifications, such as fusion tags for purification, signal peptides for secretion, or mutations to eliminate glycosylation sites, depending on the intended use. For instance, if U100 targets a cell-surface receptor involved in disease pathways, its structure might be optimized to improve receptor binding or resist enzymatic cleavage in serum.
U100's applications span therapeutics, diagnostics, and research tools. In therapeutics, it may act as a biologic drug to neutralize pathogens, modulate immune responses, or replace dysfunctional proteins. In diagnostics, U100 could serve as an antigen in assays or a detection probe due to its high specificity. Its recombinant nature ensures batch-to-batch consistency, a critical factor for regulatory compliance and clinical reliability.
The motivation behind U100's development often relates to unmet medical needs, such as targeting drug-resistant pathogens or rare diseases lacking effective treatments. Additionally, its production aligns with cost-effective and scalable manufacturing practices, addressing limitations of traditional protein extraction methods. Ongoing research focuses on further optimizing U100's pharmacokinetics and reducing immunogenic risks to maximize its translational potential.
×
